Advancing Confident Diagnosis and Early Prediction for Preeclampsia

Diagnostic Performance

Validated

Predictive Performance

To-be-validated

A blood draw quantifies biomarker proteins on circulating vascular cells — confirming preeclampsia after symptoms appear and predicting it before.

Patent-Pending Technology

Our test uses a single cutoff value and delivers strong diagnostic performance across a broad, inclusive cohort, including pregnancies with chronic hypertension, diabetes, IVF conception, multiple gestation, obesity, and maternal age 35 or older.

Specificity

71%

Sensitivity

83%

AUC

0.77

Single Clear Readout

Provides one straightforward result using a single validated cutoff value.

Inclusive Cohort

Validated across both uncomplicated and high-risk pregnancies, including chronic hypertension, diabetes, IVF, twins, obesity, and maternal age 35 or older.

Simple Blood Draw

Requires a standard 6–10 mL blood draw, under 4 hours of processing time, and only routine clinical laboratory equipment.

Test Performance Data
(coming soon)

Backed by several non-dilutive grant funding

National Science Foundation (NSF), National Institute of Health (NIH), Institution of Translational Health Sciences (ITHS) at the University of Washington (UW), We-REACH at UW, and CoMotion at UW. 

nsf logo
we reach 750x422 1
iths logo horizontal color 600px
comotion

Cheri Fang

Co-founder/CEO

Princess Imoukhuede

Co-founder/President